CA2932529C - Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain - Google Patents
Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain Download PDFInfo
- Publication number
- CA2932529C CA2932529C CA2932529A CA2932529A CA2932529C CA 2932529 C CA2932529 C CA 2932529C CA 2932529 A CA2932529 A CA 2932529A CA 2932529 A CA2932529 A CA 2932529A CA 2932529 C CA2932529 C CA 2932529C
- Authority
- CA
- Canada
- Prior art keywords
- pain
- mmol
- compound
- inden
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013-262743 | 2013-12-19 | ||
| JP2013262743 | 2013-12-19 | ||
| PCT/JP2014/083374 WO2015093515A1 (ja) | 2013-12-19 | 2014-12-17 | １－インダンスルファミド誘導体を含む疼痛の治療および／または予防剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2932529A1 CA2932529A1 (en) | 2015-06-25 |
| CA2932529C true CA2932529C (en) | 2022-03-22 |
Family
ID=53402860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2932529A Active CA2932529C (en) | 2013-12-19 | 2014-12-17 | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9610262B2 (https=) |
| EP (1) | EP3085369B1 (https=) |
| JP (1) | JP6518595B2 (https=) |
| KR (1) | KR102250214B1 (https=) |
| CN (1) | CN105792821B (https=) |
| AU (1) | AU2014367781B2 (https=) |
| BR (1) | BR112016012833B1 (https=) |
| CA (1) | CA2932529C (https=) |
| ES (1) | ES2673876T3 (https=) |
| IL (1) | IL246036B (https=) |
| MX (1) | MX370898B (https=) |
| RU (1) | RU2678571C1 (https=) |
| SG (1) | SG11201604484UA (https=) |
| WO (1) | WO2015093515A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200132858A (ko) * | 2018-03-20 | 2020-11-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간질 치료제 |
| TW202345782A (zh) * | 2022-04-27 | 2023-12-01 | 日商衛材R&D企管股份有限公司 | 帕金森氏症治療用醫藥組成物 |
| KR102815521B1 (ko) | 2022-11-11 | 2025-06-04 | 덕산에테르씨티 주식회사 | 내화성능 및 강도가 보강된 압력용기 |
| KR102803991B1 (ko) | 2022-11-11 | 2025-05-13 | 덕산에테르씨티 주식회사 | 내화성능 및 강도가 보강된 압력용기 |
| KR102815520B1 (ko) | 2022-11-11 | 2025-06-04 | 덕산에테르씨티 주식회사 | 내화성능 및 강도가 보강된 압력용기 |
| KR102917062B1 (ko) | 2023-11-01 | 2026-02-05 | 덕산에테르씨티 주식회사 | 압력 용기의 숄더부 보호용 커버 |
| KR102917063B1 (ko) | 2023-11-01 | 2026-02-23 | 덕산에테르씨티 주식회사 | 압력 용기의 숄더부 보호용 커버 |
| KR102917061B1 (ko) | 2023-11-01 | 2026-02-05 | 덕산에테르씨티 주식회사 | 압력 용기의 숄더부 보호용 커버 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US20070191452A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| EP2417101B1 (en) * | 2009-04-09 | 2013-10-23 | Merck Sharp & Dohme B.V. | Indane derivatives |
| TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| RU2508295C2 (ru) * | 2012-03-22 | 2014-02-27 | Общество с ограниченной ответственностью "Биофармокс" | Синтетические пептиды с ненаркотическим типом анальгетического действия |
| MY169073A (en) * | 2012-06-21 | 2019-02-13 | Eisai R&D Man Co Ltd | Indanesulfamide derivative |
-
2014
- 2014-12-17 AU AU2014367781A patent/AU2014367781B2/en active Active
- 2014-12-17 MX MX2016007370A patent/MX370898B/es active IP Right Grant
- 2014-12-17 CA CA2932529A patent/CA2932529C/en active Active
- 2014-12-17 ES ES14871860.4T patent/ES2673876T3/es active Active
- 2014-12-17 SG SG11201604484UA patent/SG11201604484UA/en unknown
- 2014-12-17 RU RU2016122189A patent/RU2678571C1/ru active
- 2014-12-17 WO PCT/JP2014/083374 patent/WO2015093515A1/ja not_active Ceased
- 2014-12-17 CN CN201480066081.3A patent/CN105792821B/zh active Active
- 2014-12-17 BR BR112016012833-8A patent/BR112016012833B1/pt active IP Right Grant
- 2014-12-17 KR KR1020167014850A patent/KR102250214B1/ko active Active
- 2014-12-17 EP EP14871860.4A patent/EP3085369B1/en active Active
- 2014-12-17 US US15/102,046 patent/US9610262B2/en active Active
- 2014-12-17 JP JP2015553575A patent/JP6518595B2/ja active Active
-
2016
- 2016-06-05 IL IL246036A patent/IL246036B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL246036B (en) | 2018-11-29 |
| AU2014367781B2 (en) | 2019-07-04 |
| JPWO2015093515A1 (ja) | 2017-03-23 |
| EP3085369B1 (en) | 2018-04-04 |
| KR102250214B1 (ko) | 2021-05-07 |
| EP3085369A1 (en) | 2016-10-26 |
| US9610262B2 (en) | 2017-04-04 |
| WO2015093515A1 (ja) | 2015-06-25 |
| SG11201604484UA (en) | 2016-07-28 |
| ES2673876T3 (es) | 2018-06-26 |
| EP3085369A4 (en) | 2017-05-10 |
| RU2016122189A (ru) | 2018-01-24 |
| RU2678571C1 (ru) | 2019-01-30 |
| CN105792821A (zh) | 2016-07-20 |
| CA2932529A1 (en) | 2015-06-25 |
| US20160303058A1 (en) | 2016-10-20 |
| JP6518595B2 (ja) | 2019-05-22 |
| IL246036A0 (en) | 2016-07-31 |
| BR112016012833B1 (pt) | 2022-11-16 |
| BR112016012833A2 (https=) | 2017-08-08 |
| AU2014367781A1 (en) | 2016-06-23 |
| CN105792821B (zh) | 2018-05-04 |
| MX370898B (es) | 2020-01-09 |
| KR20160106053A (ko) | 2016-09-09 |
| MX2016007370A (es) | 2016-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2932529C (en) | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain | |
| US11826363B2 (en) | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient | |
| KR101584823B1 (ko) | 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법 | |
| EP3421039B1 (en) | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor | |
| JP4932994B2 (ja) | 抗癌性カルシウムチャンネル遮断薬 | |
| CA2731685A1 (en) | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | |
| CA2698271C (en) | Multikinase inhibitors for use in the treatment of cancer | |
| WO2009047298A2 (en) | Dimers of harmol or of its derivatives and uses thereof | |
| EP3151829A1 (en) | Novel sesquiterpene derivatives and their use in inflammation and cancer treatment | |
| CA2873710A1 (en) | Quinazoline-7-ether compounds and methods of use | |
| WO2008011483A2 (en) | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds | |
| EP2184073A1 (en) | Therapeutic agent for cancer with resistance to protease inhibitor | |
| KR20000016750A (ko) | Naaladase 억제를 이용한 암의 치료방법. | |
| WO2010010934A1 (ja) | ｐ－置換アリールアセトアミドを有するヘテロシクリデン誘導体 | |
| JP2021073171A (ja) | （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物 | |
| JPWO2019031471A1 (ja) | 脂肪性肝疾患の治療剤及び肥満症の治療剤 | |
| WO2020263893A1 (en) | Cannabinoid conjugate molecules | |
| JP2012525362A5 (https=) | ||
| KR20200070273A (ko) | 중독을 예방하기 위한 병용 요법 | |
| WO2012131096A1 (en) | Novel heterocyclic compounds as modulators of sphingolipid signaling and uses thereof | |
| CN109939109B (zh) | N-噻唑-乙酰胺衍生物作为破骨细胞分化抑制剂在制备抗骨质疏松药物中的应用 | |
| JP2005035895A (ja) | 高カルシウム血症および骨疾患治療剤 | |
| TWI387455B (zh) | 苯并-稠合的雜環磺醯胺衍生物用於治療疼痛之用途 | |
| KR102547925B1 (ko) | 암 치료를 위한 치료제로서의 4-옥소-n-(4-히드록시페닐)레틴아미드 유도체 | |
| EP2258370A1 (en) | Treatment of malignant diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191011 |